Objective
To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM).Methods
Participants (aged 36-85 years) who completed the core study (RESILIENT [Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscl...